香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因依賴該等內容 而引致的任何損失承擔任何責任。 北 京 市 春 立 正 達 醫 療 器 械 股 份 有 限 公 司 Beijing Chunlizhengda Medical Instruments Co., Ltd.* （ 於 中 華 人 民 共 和 國 註 冊 成 立 的 股 份 有 限 公 司 ） （股 份 代 號：1858） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條由北京市春立正 達醫療器械股份有限公司（「本公司」）作出。 茲載列本公司在上海證券交易所網站刊登之《2025年年度報告摘要》，僅供參閱。 承董事會命 北京市春立正達醫療器械股份有限公司 董事長 史文玲 中國北京，2026年3月31日 截至本公告日期，本公司執行董事為史文玲女士、史春寶先生、岳術俊女士及解鳳寶先生；本公 司非執行董事為王鑫先生；及本公司獨立非執行董事為徐泓女士、翁杰先生及黃德盛先生。 * 僅供識別 北京市春立正达医疗器械股份有限公司202 ...

Group 1 - The core point of the article highlights that southbound funds have increased their holdings in Chunli Medical (01858.HK) by 168,200 shares on February 27, with a total net increase of 152,000 shares over the last five trading days [1] - Over the past 20 trading days, southbound funds have reduced their holdings in Chunli Medical for 12 days, resulting in a cumulative net reduction of 1,129,700 shares [1] - As of now, southbound funds hold 41,216,800 shares of Chunli Medical, accounting for 43.31% of the company's total issued ordinary shares [1] Group 2 - Chunli Medical is primarily engaged in the research, production, and sales of implantable orthopedic medical devices in China [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - The joint prosthetics product line covers four major human joints: hip, knee, shoulder, and elbow, with products sold in both domestic and international markets [1]

Group 1 - The core viewpoint of the news highlights the trading performance and financing activities of Spring Medical, indicating a net financing purchase of 271.09 million yuan on February 25, with a total financing and securities balance of 73.01 million yuan [1] - Spring Medical's financing balance of 73.01 million yuan accounts for 1.14% of its circulating market value, which is above the 90th percentile level over the past year, indicating a high level of financing activity [1] - The company has not engaged in any short selling activities on February 25, with a short selling balance of 4458.00 yuan, which is also above the 70th percentile level over the past year, suggesting a relatively high level of short selling interest [1] Group 2 - Spring Medical, established on February 12, 1998, specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prosthetics and spinal implants [2] - The company reported a revenue of 756 million yuan for the period from January to September 2025, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, reflecting a significant increase of 213.21% year-on-year [2] - As of September 30, 2025, the number of shareholders increased by 4.12% to 6164, while the average circulating shares per person decreased by 3.95% to 46906 shares [2] Group 3 - Spring Medical has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan distributed over the past three years [3] - Among the top ten circulating shareholders as of September 30, 2025, Hong Kong Central Clearing Limited is the fourth largest new shareholder with 2.9585 million shares, while China Europe Economic Selection Mixed A and Ping An Low Carbon Economy Mixed A are also notable new shareholders [3] - South Pharmaceutical Health Flexible Allocation Mixed A has exited the list of the top ten circulating shareholders [3]

Group 1 - The core viewpoint of the news is that Spring Medical has shown significant financial performance with a notable increase in revenue and net profit, indicating strong growth potential in the orthopedic medical device sector [2][3]. - As of February 24, Spring Medical's stock price increased by 0.58%, with a trading volume of 34.10 million yuan, and a net financing purchase of 11.70 million yuan, reflecting active investor interest [1]. - The company's financing balance reached 70.30 million yuan, accounting for 1.09% of its market capitalization, which is above the 90th percentile of the past year, indicating a high level of investor engagement [1]. Group 2 - Spring Medical specializes in the research, production, and sales of implantable orthopedic medical devices, with its main products including joint prostheses and spinal implants, which are exported to various regions worldwide [2]. - For the period from January to September 2025, Spring Medical reported a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit of 192 million yuan, which is a 213.21% increase compared to the previous year [2]. - The company has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan distributed over the past three years, indicating a commitment to returning value to shareholders [3].

Core Viewpoint - Southbound funds increased their holdings in Chuangli Medical (01858.HK) by 61,000 shares on February 13, 2023, despite a net reduction of 338,800 shares over the past five trading days [1] Group 1: Southbound Fund Activity - In the last five trading days, there were three days of net reductions in holdings by southbound funds, totaling 338,800 shares [1] - Over the past 20 trading days, there were ten days of net reductions, amounting to 246,800 shares [1] - As of now, southbound funds hold 41,125,800 shares of Chuangli Medical, representing 43.21% of the company's issued ordinary shares [1] Group 2: Company Overview - Beijing Chuangli Zhengda Medical Device Co., Ltd. primarily engages in the research, development, production, and sales of implantable orthopedic medical devices [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - Joint prosthetics cover four major human joints: hip, knee, shoulder, and elbow, with products sold in both domestic and international markets [1]

Core Viewpoint - Spring Medical has experienced a decline in stock price and trading volume, with a notable drop in recent trading days, indicating potential investor concerns about the company's performance and market position [1]. Group 1: Company Overview - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, is based in Tongzhou District, Beijing, and specializes in the research, production, and sales of implantable orthopedic medical devices [1]. - The company's main products include joint prosthetics (hip, knee, shoulder, elbow) and a full range of spinal implant products [1]. - The revenue composition of the company is predominantly from medical device products at 99.89%, with other sources contributing 0.11% [1]. Group 2: Financial Performance - For the period from January to September 2025, Spring Medical reported a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, which is a significant increase of 213.21% [2]. - Since its A-share listing, the company has distributed a total of 440 million yuan in dividends, with 390 million yuan distributed over the past three years [3]. Group 3: Market Activity - As of February 12, 2023, Spring Medical's stock price was 22.40 yuan per share, with a market capitalization of 8.592 billion yuan [1]. - The stock has seen a year-to-date decline of 1.20%, a 5-day drop of 3.16%, an 18.13% decrease over the past 20 days, and a 12.98% decline over the last 60 days [1]. - The company has experienced a net outflow of 1.0456 million yuan in principal funds, with large orders accounting for 3.27% of purchases and 8.11% of sales [1].

Group 1 - The core business of the company is focused on the research, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [2] - As of September 30, 2025, the company achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a significant increase of 213.21% [2] - The company has distributed a total of 440 million yuan in dividends since its A-share listing, with 390 million yuan distributed over the past three years [3] Group 2 - As of February 10, 2023, the company's financing balance reached 50 million yuan, accounting for 0.75% of its market capitalization, indicating a high level of financing activity [1] - The company had a net financing purchase of 1.46 million yuan on February 10, 2023, with a total financing buy of 4.19 million yuan and repayment of 2.73 million yuan [1] - The company’s stock has seen an increase in shareholder accounts, with a total of 6,164 shareholders as of September 30, 2025, reflecting a 4.12% increase [2]

Core Viewpoint - Southbound funds have reduced their holdings in Spring Medical (01858.HK) by 31,000 shares on February 10, indicating a trend of net selling over recent trading days [1] Group 1: Southbound Fund Activity - In the last 5 trading days, southbound funds have reduced their holdings on 4 days, with a total net reduction of 789,500 shares [1] - Over the past 20 trading days, there have been 11 days of net selling, resulting in a cumulative net reduction of 901,200 shares [1] - Currently, southbound funds hold 41,446,300 shares of Spring Medical, accounting for 43.55% of the company's total issued ordinary shares [1] Group 2: Company Overview - Beijing Spring Medical Co., Ltd. specializes in the research, production, and sales of implantable orthopedic medical devices [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - Joint prosthetics cover major human joints such as hip, knee, shoulder, and elbow, with products sold in both domestic and international markets [1]

Group 1 - The core viewpoint of the news highlights the trading performance and financial metrics of Spring Medical, indicating a slight decline in stock price and notable financing activities on February 9 [1] - On February 9, Spring Medical's stock price fell by 0.35%, with a trading volume of 34.99 million yuan. The financing buy-in amounted to 5.24 million yuan, while the financing repayment was 3.77 million yuan, resulting in a net financing buy of 1.48 million yuan [1] - As of February 9, the total financing and securities lending balance for Spring Medical reached 48.55 million yuan, with the financing balance accounting for 0.73% of the circulating market value, indicating a high level compared to the past year [1] Group 2 - Spring Medical, established on February 12, 1998, and listed on December 30, 2021, specializes in the research, production, and sales of implantable orthopedic medical devices, including joint prosthetics and spinal implants [2] - The company's main products include hip, knee, shoulder, and elbow joint prosthetics, as well as a full range of spinal fixation systems. Its products are exported to various regions, including Asia, South America, Africa, Oceania, and Europe [2] - For the period from January to September 2025, Spring Medical reported a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, reflecting a significant increase of 213.21% [2] Group 3 - Since its A-share listing, Spring Medical has distributed a total of 440 million yuan in dividends, with 390 million yuan distributed over the past three years [3] - As of September 30, 2025, the number of shareholders for Spring Medical increased by 4.12% to 6,164, while the average circulating shares per person decreased by 3.95% to 46,906 shares [2][3] - Among the top ten circulating shareholders, new entrants include Hong Kong Central Clearing Limited and China Europe Economic Growth Mixed A, holding 2.96 million shares and 2.83 million shares, respectively [3]

Core Viewpoint - Southbound funds increased their holdings in Chuangli Medical (01858.HK) by 12,700 shares on February 9, indicating a fluctuating interest from these investors in the company [1] Group 1: Southbound Fund Activity - Over the past five trading days, there were three days of net reductions in holdings by southbound funds, totaling a net decrease of 674,000 shares [1] - In the last twenty trading days, there were ten days of net reductions, with a cumulative net decrease of 769,000 shares [1] - Currently, southbound funds hold 41,477,300 shares of Chuangli Medical, accounting for 43.59% of the company's total issued ordinary shares [1] Group 2: Company Overview - Beijing Chuangli Zhengda Medical Device Co., Ltd. specializes in the research, development, production, and sales of implantable orthopedic medical devices [1] - The company's main products include joint prosthetics, spinal implants, trauma products, sports medicine products, platelet-rich plasma (PRP) products, oral products, and surgical robots [1] - Joint prosthetics cover four major human joints: hip, knee, shoulder, and elbow, with products sold in both domestic and international markets [1]